Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Superoxide Dismutase
Motor Neuron Disease
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
RNA-Binding Protein FUS
A multifunctional heterogeneous-nuclear ribonucleoprotein that may play a role in homologous DNA pairing and recombination. The N-terminal portion of protein is a potent transcriptional activator, while the C terminus is required for RNA binding. The name FUS refers to the fact that genetic recombination events result in fusion oncogene proteins (ONCOGENE PROTEINS, FUSION) that contain the N-terminal region of this protein. These fusion proteins have been found in myxoid liposarcoma (LIPOSARCOMA, MYXOID) and acute myeloid leukemia.
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Spinal Cord
DNA Repeat Expansion
Frontotemporal Dementia
Guam
An island in Micronesia, east of the Philippines, the largest and southernmost of the Marianas. Its capital is Agana. It was discovered by Magellan in 1521 and occupied by Spain in 1565. They ceded it to the United States in 1898. It is an unincorporated territory of the United States, administered by the Department of the Interior since 1950. The derivation of the name Guam is in dispute. (From Webster's New Geographical Dictionary, 1988, p471)
Riluzole
Frontotemporal Lobar Degeneration
Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.
Inclusion Bodies
A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed)
Mice, Transgenic
Nerve Degeneration
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Disease Models, Animal
Neurodegenerative Diseases
Mutation
Fasciculation
Involuntary contraction of the muscle fibers innervated by a motor unit. Fasciculations can often by visualized and take the form of a muscle twitch or dimpling under the skin, but usually do not generate sufficient force to move a limb. They may represent a benign condition or occur as a manifestation of MOTOR NEURON DISEASE or PERIPHERAL NERVOUS SYSTEM DISEASES. (Adams et al., Principles of Neurology, 6th ed, p1294)
TDP-43 Proteinopathies
Diseases characterized by the presence of abnormally phosphorylated, ubiquitinated, and cleaved DNA-binding protein TDP-43 in affected brain and spinal cord. Inclusions of the pathologic protein in neurons and glia, without the presence of AMYLOID, is the major feature of these conditions, thus making these proteinopathies distinct from most other neurogenerative disorders in which protein misfolding leads to brain amyloidosis. Both frontotemporal lobar degeneration and AMYOTROPHIC LATERAL SCLEROSIS exhibit this common method of pathogenesis and thus they may represent two extremes of a continuous clinicopathological spectrum of one disease.
Anterior Horn Cells
Sclerosis
Bulbar Palsy, Progressive
A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900)
Neurofilament Proteins
Type III intermediate filament proteins that assemble into neurofilaments, the major cytoskeletal element in nerve axons and dendrites. They consist of three distinct polypeptides, the neurofilament triplet. Types I, II, and IV intermediate filament proteins form other cytoskeletal elements such as keratins and lamins. It appears that the metabolism of neurofilaments is disturbed in Alzheimer's disease, as indicated by the presence of neurofilament epitopes in the neurofibrillary tangles, as well as by the severe reduction of the expression of the gene for the light neurofilament subunit of the neurofilament triplet in brains of Alzheimer's patients. (Can J Neurol Sci 1990 Aug;17(3):302)
Disease Progression
Rats, Transgenic
Brain
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Age of Onset
Tuberous Sclerosis
Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
Lithium Carbonate
Mutation, Missense
Cycas
Astrocytes
A class of large neuroglial (macroglial) cells in the central nervous system - the largest and most numerous neuroglial cells in the brain and spinal cord. Astrocytes (from "star" cells) are irregularly shaped with many long processes, including those with "end feet" which form the glial (limiting) membrane and directly and indirectly contribute to the BLOOD-BRAIN BARRIER. They regulate the extracellular ionic and chemical environment, and "reactive astrocytes" (along with MICROGLIA) respond to injury.
Neurons
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
Excitatory Amino Acid Transporter 2
DNA-Binding Proteins
Microglia
The third type of glial cell, along with astrocytes and oligodendrocytes (which together form the macroglia). Microglia vary in appearance depending on developmental stage, functional state, and anatomical location; subtype terms include ramified, perivascular, ameboid, resting, and activated. Microglia clearly are capable of phagocytosis and play an important role in a wide spectrum of neuropathologies. They have also been suggested to act in several other roles including in secretion (e.g., of cytokines and neural growth factors), in immunological processing (e.g., antigen presentation), and in central nervous system development and remodeling.
Pyramidal Tracts
Pseudobulbar Palsy
A syndrome characterized by DYSARTHRIA, dysphagia, dysphonia, impairment of voluntary movements of tongue and facial muscles, and emotional lability. This condition is caused by diseases that affect the motor fibers that travel from the cerebral cortex to the lower BRAIN STEM (i.e., corticobulbar tracts); including MULTIPLE SCLEROSIS; MOTOR NEURON DISEASE; and CEREBROVASCULAR DISORDERS. (From Adams et al., Principles of Neurology, 6th ed, p489)
Rotarod Performance Test
A performance test based on forced MOTOR ACTIVITY on a rotating rod, usually by a rodent. Parameters include the riding time (seconds) or endurance. Test is used to evaluate balance and coordination of the subjects, particular in experimental animal models for neurological disorders and drug effects.
Noninvasive Ventilation
Amino Acid Substitution
The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.
Ribonuclease, Pancreatic
Axonal Transport
Neuromuscular Diseases
Case-Control Studies
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Animals, Genetically Modified
Muscle Weakness
A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
Mitochondria
Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed)
Cell Death
Peripherins
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Phenotype
Electromyography
Laughter
Magnetic Resonance Imaging
Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
Neuroglia
The non-neuronal cells of the nervous system. They not only provide physical support, but also respond to injury, regulate the ionic and chemical composition of the extracellular milieu, participate in the BLOOD-BRAIN BARRIER and BLOOD-RETINAL BARRIER, form the myelin insulation of nervous pathways, guide neuronal migration during development, and exchange metabolites with neurons. Neuroglia have high-affinity transmitter uptake systems, voltage-dependent and transmitter-gated ion channels, and can release transmitters, but their role in signaling (as in many other functions) is unclear.
Central Nervous System
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Pedigree
Paralysis
Communication Aids for Disabled
Equipment that provides mentally or physically disabled persons with a means of communication. The aids include display boards, typewriters, cathode ray tubes, computers, and speech synthesizers. The output of such aids includes written words, artificial speech, language signs, Morse code, and pictures.
Copper
Tracheostomy
Glial Fibrillary Acidic Protein
Gliosis
Muscle, Skeletal
Glutamic Acid
Chromosomes, Human, Pair 9
Ubiquitin
A highly conserved 76-amino acid peptide universally found in eukaryotic cells that functions as a marker for intracellular PROTEIN TRANSPORT and degradation. Ubiquitin becomes activated through a series of complicated steps and forms an isopeptide bond to lysine residues of specific proteins within the cell. These "ubiquitinated" proteins can be recognized and degraded by proteosomes or be transported to specific compartments within the cell.
Immunohistochemistry
Atrophy
Motor Cortex
Area of the FRONTAL LOBE concerned with primary motor control located in the dorsal PRECENTRAL GYRUS immediately anterior to the central sulcus. It is comprised of three areas: the primary motor cortex located on the anterior paracentral lobule on the medial surface of the brain; the premotor cortex located anterior to the primary motor cortex; and the supplementary motor area located on the midline surface of the hemisphere anterior to the primary motor cortex.
Genetic Predisposition to Disease
Pyrazolones
Respiratory Insufficiency
Muscular Atrophy, Spinal
A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)
Oxidative Stress
Nervous System Diseases
Glycine
Multiple Sclerosis, Chronic Progressive
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
Cell Survival
Proteins
Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
Neuroimaging
A clinical study of motor evoked potentials using a triple stimulation technique. (1/1872)
Amplitudes of motor evoked potentials (MEPs) are usually much smaller than those of motor responses to maximal peripheral nerve stimulation, and show marked variation between normal subjects and from one stimulus to another. Consequently, amplitude measurements have low sensitivity to detect central motor conduction failures due to the broad range of normal values. Since these characteristics are mostly due to varying desynchronization of the descending action potentials, causing different degrees of phase cancellation, we applied the recently developed triple stimulation technique (TST) to study corticospinal conduction to 489 abductor digiti minimi muscles of 271 unselected patients referred for possible corticospinal dysfunction. The TST allows resynchronization of the MEP, and thereby a quantification of the proportion of motor units activated by the transcranial stimulus. TST results were compared with those of conventional MEPs. In 212 of 489 sides, abnormal TST responses suggested conduction failure of various degrees. By contrast, conventional MEPs detected conduction failures in only 77 of 489 sides. The TST was therefore 2.75 times more sensitive than conventional MEPs in disclosing corticospinal conduction failures. When the results of the TST and conventional MEPs were combined, 225 sides were abnormal: 145 sides showed central conduction failure, 13 sides central conduction slowing and 67 sides both conduction failure and slowing. It is concluded that the TST is a valuable addition to the study of MEPs, since it improves detection and gives quantitative information on central conduction failure, an abnormality which appears to be much more frequent than conduction slowing. This new technique will be useful in following the natural course and the benefit of treatments in disorders affecting central motor conduction. (+info)Nitric oxide, mitochondria and neurological disease. (2/1872)
Damage to the mitochondrial electron transport chain has been suggested to be an important factor in the pathogenesis of a range of neurological disorders, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and amyotrophic lateral sclerosis. There is also a growing body of evidence to implicate excessive or inappropriate generation of nitric oxide (NO) in these disorders. It is now well documented that NO and its toxic metabolite, peroxynitrite (ONOO-), can inhibit components of the mitochondrial respiratory chain leading, if damage is severe enough, to a cellular energy deficiency state. Within the brain, the susceptibility of different brain cell types to NO and ONOO- exposure may be dependent on factors such as the intracellular reduced glutathione (GSH) concentration and an ability to increase glycolytic flux in the face of mitochondrial damage. Thus neurones, in contrast to astrocytes, appear particularly vulnerable to the action of these molecules. Following cytokine exposure, astrocytes can increase NO generation, due to de novo synthesis of the inducible form of nitric oxide synthase (NOS). Whilst the NO/ONOO- so formed may not affect astrocyte survival, these molecules may diffuse out to cause mitochondrial damage, and possibly cell death, to other cells, such as neurones, in close proximity. Evidence is now available to support this scenario for neurological disorders, such as multiple sclerosis. In other conditions, such as ischaemia, increased availability of glutamate may lead to an activation of a calcium-dependent nitric oxide synthase associated with neurones. Such increased/inappropriate NO formation may contribute to energy depletion and neuronal cell death. The evidence available for NO/ONOO--mediated mitochondrial damage in various neurological disorders is considered and potential therapeutic strategies are proposed. (+info)The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. (3/1872)
It has been reported that expression of familial amyotrophic lateral sclerosis (FALS)-associated mutant Cu/Zn superoxide dismutase-1 (SOD) induces apoptosis of neuronal cells in culture associated with an increase in reactive oxygen species. SOD recently has been shown to prevent calcineurin inactivation, initiating the present investigations examining the role of calcineurin in mutant SOD-induced cell death. Wild-type or mutant SOD was expressed in neuronal cells by infection with replication-deficient adenoviruses. PC12 cells overexpressing human wild-type SOD exhibited higher calcineurin activity than cells expressing FALS-related mutant SOD (SODV148G); however, cells expressing SODV148G had calcineurin activity equal to mock-infected cells, suggesting that cell death induced by mutant SOD was not related to a decrease in calcineurin activity. Calcineurin antagonists such as cyclosporin A and FK506, as well as nonimmunosuppressant analogs of cyclosporin A, significantly enhanced SODV148G- and SODA4V-induced cell death. Because both groups of drugs inhibit the rotamase activity of cyclophilins (CyP), but only the immunosuppressant analogs inhibit calcineurin activity, these data suggest that rotamase inhibition underlies the enhanced cell death after SODV148G expression. The importance of rotamase activity in mutant SOD-mediated apoptosis was supported by experiments showing that overexpressed wild-type cyclophilin A (CyPA), but not CyPA with a rotamase active site point mutation, protected cells from death after SODV148G expression. These data suggest that mutant SOD produces a greater need for rotamase and, also, highlights possible new therapeutic strategies in FALS. (+info)Release of copper ions from the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants. (4/1872)
Point mutations of Cu,Zn-superoxide dismutase (SOD) have been linked to familial amyotrophic lateral sclerosis (FALS). We reported that the Swedish FALS Cu,Zn-SOD mutant, D90A, exhibited an enhanced hydroxyl radical-generating activity, while its dismutation activity was identical to that of the wild-type enzyme (Kim et al. 1998a; 1998b). Transgenic mice that express a mutant Cu,Zn-SOD, Gly93 --> Ala (G93A), have been shown to develop amyotrophic lateral sclerosis (ALS) symptoms. We cloned the cDNA for the FALS G93A mutant, overexpressed the protein in E. coli cells, purified the protein, and studied its enzymic activities. Our results showed that the G93A, the D90A, and the wild-type enzymes have identical dismutation activity. However, the hydroxyl radical-generating activity of the G93A mutant was enhanced relative to those of the D90A and the wild-type enzyme (wild-type < D90A < G93A). These higher free radical-generating activities of mutants facilitated the release of copper ions from their own molecules (wild-type < D90A < G93A). The released copper ions can enhance the Fenton-like reaction to produce hydroxyl radicals and play a major role in the oxidative damage of macromolecules. Thus, the FALS symptoms may be associated with the enhancements in both the free radical-generating activity and the releasing of copper ions from the mutant enzyme. (+info)Amyotrophic lateral sclerosis: Lou Gehrig's disease. (5/1872)
Amyotrophic lateral sclerosis (ALS), commonly called Lou Gehrig's disease, is a progressive neuromuscular condition characterized by weakness, muscle wasting, fasciculations and increased reflexes. Approximately 30,000 Americans currently have the disease. The annual incidence rate is one to two cases per 100,000. The disease is most commonly diagnosed in middle age and affects more men than women. It usually presents with problems in dexterity or gait resulting from muscle weakness. Difficulty in speaking or swallowing is the initial symptom in the bulbar form of the disease. Over a period of months or years, patients with ALS develop severe, progressive muscular weakness and other symptoms caused by loss of function in both upper and lower motor neurons. Sphincter control, sensory function, intellectual abilities and skin integrity are preserved. Patients become completely disabled, often requiring ventilatory support and gastrostomy. Death usually occurs within five years of diagnosis and is attributed to respiratory failure or cachexia. The etiology of the disease is unknown. Current research is focused on abnormalities of neuronal cell metabolism involving glutamate and the role of potential neurotoxins and neurotrophic factors. New drugs are being developed based on these theories. Current management involves aggressive, individualized alleviation of symptoms and complications. (+info)Atypical form of amyotrophic lateral sclerosis. (6/1872)
OBJECTIVE: To investigate patients with an unusual type of muscular atrophy confined to the upper limbs (proximally dominant) and the shoulder girdle, while sparing the face and the legs until the terminal stage. METHODS: Eight patients (six men and two women) were clinically examined. The age at onset ranged from 42 to 73 years, and the clinical course varied from 28 to 81 months. There was no family history of motor neuron disease in any of these patients. Necropsy was performed in two of them. RESULTS: All eight patients basically showed a similar distribution of muscular weakness and atrophy. Subluxation of the shoulder joints was found in all patients. Reflexes were absent in the upper limbs in all patients, but were almost normal in the face and legs in most patients. Pathological reflexes could be elicited in only one patient. Electromyography showed typical neurogenic changes in the limbs of all patients. Cervical MRI disclosed moderate spondylotic changes in seven patients. Antiganglioside antibodies were negative in six patients tested. Abnormal trinucleotide (CAG) repeat expansion of androgen receptor gene was not recognised in five patients examined. Bulbar involvement developed in three patients during the course of the disease. At necropsy, one patient showed degeneration of the pyramidal tracts and motor cortex including Betz cells as well as loss of spinal anterior horn cells and brainstem motor neurons, which is consistent with ALS; in another patient there was neuronal loss of anterior horn cells at the spinal cord accompanied by astrogliosis, whereas the motor cortex and brainstem motor nuclei were relatively well preserved. Intracytoplasmic inclusions such as Bunina bodies, skein-like inclusions, and Lewy body-like inclusions were found in both patients. CONCLUSION: These patients with their peculiar pattern of muscular atrophy seem to have ALS or a subtype of ALS. (+info)Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. (7/1872)
Mutations in superoxide dismutase 1 (SOD1) polypeptides cause a form of familial amyotrophic lateral sclerosis (FALS). In different kindreds, harboring different mutations, the duration of illness tends to be similar for a given mutation. For example, patients inheriting a substitution of valine for alanine at position four (A4V) average a 1.5 year life expectancy after the onset of symptoms, whereas patients harboring a substitution of arginine for histidine at position 46 (H46R) average an 18 year life expectancy after disease onset. Here, we examine a number of biochemical and biophysical properties of nine different FALS variants of SOD1 polypeptides, including enzymatic activity (which relates indirectly to the affinity of the enzyme for copper), polypeptide half-life, resistance to proteolytic degradation and solubility, in an effort to determine whether a specific property of these enzymes correlates with clinical progression. We find that although all the mutants tested appear to be soluble, the different mutants show a remarkable degree of variation with respect to activity, polypeptide half-life and resistance to proteolysis. However, these variables do not stratify in a manner that correlates with clinical progression. We conclude that the basis for the different life expectancies of patients in different kindreds of sod1-linked FALS may result from an as yet unidentified property of these mutant enzymes. (+info)Extrapyramidal involvement in amyotrophic lateral sclerosis: backward falls and retropulsion. (8/1872)
Three patients with sporadic amyotrophic lateral sclerosis (ALS) presented with a history of backward falls. Impaired postural reflexes and retropulsion accompanied clinical features of ALS. Hypokinesia, decreased arm swing, and a positive glabellar tap were noted in two of these three patients. Cognitive impairment, tremor, axial rigidity, sphincter dysfunction, nuchal dystonia, dysautonomia, and oculomotor dysfunction were absent. Brain MRI disclosed bilateral T2 weighted hyperintensities in the internal capsule and globus pallidus in one patient. Necropsy studies performed late in the course of ALS have shown degeneration in extrapyramidal sites-for example, the globus pallidus, thalamus, and substantia nigra. Clinically, backward falls and retropulsion may occur early in ALS. This may reflect extrapyramidal involvement. (+info)
Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro...
Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively...
Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients<...
Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis...
Amyotrophic Lateral Sclerosis
Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. -...
ThOuHeEd SpAcE!!!!!: Amyotrophic lateral sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) | RxWiki
Elevated levels of selenium species in cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated...
Amyotrophic Lateral Sclerosis; Lou Gehrig Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Mother With Amyotrophic Lateral Sclerosis and Daughter With Creutzfeldt-Jakob Disease | Amyotrophic Lateral Sclerosis | JAMA...
Molecular and Cellular Mechanism of Glutamate Receptors in Relation to Amyotrophic Lateral Sclerosis | BenthamScience
Environmental and Occupational Exposures and Amyotrophic Lateral Sclerosis in New England<...
Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis | Clinical Research Trial Listing ( Amyotrophic lateral sclerosis | ...
Amyotrophic Lateral Sclerosis Treatment, Treatment for Amyotrophic Lateral Sclerosis - View Doctors, Book Appointment, Consult...
Amyotrophic Lateral Sclerosis: Evaluation
Frequency and methylation status of selected retrotransposition competent L1 loci in amyotrophic lateral sclerosis | Molecular...
Misfolded superoxide dismutase-1 in sporadic and familial Amyotrophic Lateral Sclerosis
Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients
Dorfin prevents cell death by reducing mitochondrial localizing mutant superoxide dismutase 1 in a neuronal cell model of...
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis - Full Text View - ClinicalTrials.gov
High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with
amyotrophic lateral sclerosis | IRIS Univ....
Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis |...
Reduced p75NTRexpression delays disease onset only in female mice of a transgenic model of familial amyotrophic lateral...
CHARACTERISATION OF FUSED IN SARCOMA PATHOLOGY AND FUS MUTATIONS IN JUVENILE AMYOTROPHIC LATERAL SCLEROSIS WITH BASOPHILIC...
Regulation of endosomal motility and degradation by amyotrophic lateral sclerosis 2/alsin - Lai, Chen, Xie, Chengsong, Shim,...
Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. - Nuffield...
Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. -...
SETX - Wikipedia
Perdue, Bev. Proclamation, 2012-04-11, Amyotrophic Lateral Sclerosis Awareness Month :: Modern Governors Papers
Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis<...
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries : a genome-wide association study
Cortical influences drive amyotrophic lateral sclerosis | Journal of Neurology, Neurosurgery & Psychiatry
Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. - Wellcome Centre for...
Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. - Department of Psychiatry
Amyotrophic lateral sclerosis (ALS) Sample Report covering Drugs, Companies, Market & Epidemiology analysis for Amyotrophic...
The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and...
Misfolded superoxide dismutase-1 in amyotrophic lateral sclerosis
Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis - Full Text View ...
Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype<...
فبراير
Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. - Wellcome Centre for Integrative Neuroimaging
Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis? | Translational...
Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. - Nuffield Department of Clinical...
Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and small heat shock protein...
Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease...
Metallothionein is a Potential Therapeutic Strategy for Amyotrophic Lateral Sclerosis | Bentham Science
Amyotrophic Lateral Sclerosis (ALS) - Genesis HealthCare System - Zanesville, Ohio
DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial. - White Rose Research...
Amyotrophic Lateral Sclerosis | Definition of Amyotrophic Lateral Sclerosis by Merriam-Webster
Amyotrophic lateral sclerosis
Revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron ... "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 18 (sup 1): 5-10. doi ... Amyotrophic Lateral Sclerosis. CRC Press. p. 9. ISBN 978-0824729240. .. *^ Gordon PH (October 2013). "Amyotrophic Lateral ... Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic ...
Onuf's nucleus
Amyotrophic lateral sclerosis[edit]. Amyotrophic lateral sclerosis ( Lou Gehrig disease ) is a disease that causes degeneration ... In amyotrophic lateral sclerosis, Onuf's nucleus is preserved but the other anterior horn cell groups atrophy. This discovery ... Both cell types are spared by amyotrophic lateral sclerosis.[5]. *Onuf's nucleus cells are anatomically linked with the sacral ... Patients with amyotrophic lateral sclerosis also contain less RNA in their motoneurons than normal individuals. The decrease in ...
Epigenetics of neurodegenerative diseases
Amyotrophic lateral sclerosis (ALS)[edit]. Main article: Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis (ALS), ... 2.1 Amyotrophic lateral sclerosis (ALS) *2.1.1 Genetics and underlying causes. *2.1.2 Epigenetic treatment with HDAC inhibitors ... "Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice". primary. Amyotrophic ... Disease: amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Huntington's disease (HD), spinal muscular atrophy (SMA ...
Neurodegeneration
Amyotrophic lateral sclerosis (ALS)[edit]. Main article: Amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis (ALS or ... Many neurodegenerative diseases - including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and ... and Amyotrophic lateral sclerosis.[4] Neurons are particularly vulnerable to oxidative damage due to their strong metabolic ... amyotrophic lateral sclerosis, ataxia telangiectasia, Cockayne syndrome, Parkinson's disease and xeroderma pigmentosum.[17][16] ...
Infantile progressive bulbar palsy
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Sleep disorder
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Leigh syndrome
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Stiff-person syndrome
... primary lateral sclerosis, neuromyotonia, and some psychogenic disorders.[2] Tetanus, neuroleptic malignant syndrome, malignant ... hyperpyrexia, chronic spinal interneuronitis, serotonin syndrome,[30] Multiple sclerosis, Parkinson's disease,[22] and Isaacs ...
Parkinson's disease
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Essential tremor
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Idiopathic intracranial hypertension
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ... These shunts are inserted in one of the lateral ventricles of the brain, usually by stereotactic surgery, and then connected ...
Multiple system atrophy
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Chorea
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Subacute combined degeneration of spinal cord
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ... In subacute combined degeneration of spinal cord, the "combined" refers to the fact that the dorsal columns and lateral ... The pathological findings of subacute combined degeneration consist of patchy losses of myelin in the dorsal and lateral ... Posterior column dysfunction decreases vibratory sensation and proprioception (joint sense). Lateral corticospinal tract ...
Transferase
Rowland LP, Shneider NA (May 2001). "Amyotrophic lateral sclerosis". The New England Journal of Medicine. 344 (22): 1688-700. ... "Early presymptomatic cholinergic dysfunction in a murine model of amyotrophic lateral sclerosis". Brain and Behavior. 3 (2): ...
Chronic fatigue syndrome
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ... multiple sclerosis (MS), chronic hepatitis and various malignancies."[22] Medications can also cause side effects that mimic ... multiple sclerosis), and others (such as nasal obstruction from allergies, sinusitis, anatomic obstruction, autoimmune diseases ... CFS affects a person's functional status and well-being more than major medical conditions such as multiple sclerosis, ...
Hepatic encephalopathy
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Early-onset Alzheimer's disease
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Engel classification
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Cerebral edema
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Cortical blindness
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Epileptic seizure
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ... Multiple sclerosis may cause seizures. Electroconvulsive therapy (ECT) deliberately sets out to induce a seizure for the ...
Movement disorders
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
Lewy body dementia
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ...
ICD-10 Chapter VI: Diseases of the nervous system
Amyotrophic lateral sclerosis. *Primary lateral sclerosis. *Progressive bulbar palsy. *Progressive spinal muscular atrophy ... Multiple sclerosis and other demyelinating diseases of CNS (G35-G37, 340-341) ...
Cyanotoxin
Amyotrophic Lateral Sclerosis. 10: 74-78. doi:10.3109/17482960903272942. PMID 19929737. Stewart I, Seawright AA, Shaw GR (2008 ... cyanobacteria neurotoxin BMAA may be an environmental cause of neurodegenerative diseases such as amyotrophic lateral sclerosis ...
Neuroscience of aging
Amyotrophic lateral sclerosis Creutzfeldt-Jakob disease Frontotemporal Dementia Dementia with Lewy bodies Corticobasal ... Aging is also associated with many neurological and neurodegenerative disease such as amyotrophic lateral sclerosis, dementia, ... "Amyotrophic lateral sclerosis". Lancet. 377 (9769): 942-55. doi:10.1016/s0140-6736(10)61156-7. PMID 21296405. S2CID 14354178. ...
Granulocyte colony-stimulating factor
"Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis". Amyotrophic ... "Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis". Brain. 131 (Pt 12): ... phase IIb and several clinical pilot studies are published for other neurological disease such as amyotrophic lateral sclerosis ... Lateral Sclerosis. 10 (5-6): 430-1. doi:10.3109/17482960802588059. PMID 19922135. S2CID 43087598. Acosta SA, Tajiri N, ...
Deaths in November 2014 - Simple English Wikipedia, the free encyclopedia
... amyotrophic lateral sclerosis.[52] ...
MT-TI
Finsterer, J (January 2003). "Mitochondriopathy mimicking amyotrophic lateral sclerosis". The Neurologist. 9 (1): 45-8. doi: ...
Olfactory system
... amyotrophic lateral sclerosis, and schizophrenia. These diseases have more moderate effects on the olfactory system than ...
Superoxide dismutase
Mutations in the first SOD enzyme (SOD1) can cause familial amyotrophic lateral sclerosis (ALS, a form of motor neuron disease ... "Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis". J. Biol. Chem. 283 (23): 16169-77. doi: ... "Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase". Science. 261 (5124): 1047-51. doi:10.1126/ ... "SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis". Neurobiology of Disease. 39 (2): 198-203. doi:10.1016/j.nbd. ...
Olfactory ensheathing cells
... amyotrophic lateral sclerosis, and other neurodegenerative diseases. Researchers suggest that these cells possess a unique ...
Proteasome
... amyotrophic lateral sclerosis (ALS),[127] Huntington's disease,[126] Creutzfeldt-Jakob disease,[128] and motor neuron diseases ... "Morphometrical reappraisal of motor neuron system of Pick's disease and amyotrophic lateral sclerosis with dementia". Acta ... The presence of 20S proteasomes in bacteria may result from lateral gene transfer, while the diversification of subunits among ...
Neuroscience
Neurology works with diseases of the central and peripheral nervous systems, such as amyotrophic lateral sclerosis (ALS) and ... Illustration from Gray's Anatomy (1918) of a lateral view of the human brain, featuring the hippocampus among other ...
睡眠性交症
ALS(英语:Template:Amyotrophic lateral sclerosis). *症狀 *頭頸部 ...
Limb-girdle muscular dystrophy
Peripherin: Amyotrophic lateral sclerosis. 4. *Neurofilament: Parkinson's disease. *Charcot-Marie-Tooth disease 1F, 2E ...
Transcranial magnetic stimulation
TMS has shown potential with neurologic conditions such as Alzheimer's disease,[4] amyotrophic lateral sclerosis,[4][35] ... "Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease". The ... multiple sclerosis,[4] schizophrenia,[4][10] and traumatic brain injury.[40] ...
Demyelinating disease
Primary lateral sclerosis. *Pseudobulbar palsy. *Hereditary spastic paraplegia. *LMN only: *Distal hereditary motor ... Minegar, Alireza (2003). "Blood-Brain Barrier Disruption in Multiple Sclerosis". Multiple Sclerosis Journal. Sage Journals. 9 ( ... See also: Multiple sclerosis § Medications, and Management of multiple sclerosis. Treatments are patient-specific and depend on ... Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". Neurol. Sci. 22 (2): 117-39. doi:10.1007 ...
NMDA receptor
Huntington's disease and amyotrophic lateral sclerosis.[13][14][15][16] Blocking of NMDA receptors could therefore, in theory, ...
Neurofilament light polypeptide
It is a useful marker for disease monitoring in amyotrophic lateral sclerosis,[9] multiple sclerosis,[10] familial Alzheimer's ... including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and ... Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C (November 1996). "Patients with amyotrophic lateral sclerosis ... "Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis". PLOS One. 11 (10): ...
beta-Methylamino-L-alanine
Chronic dietary exposure to BMAA is now considered to be a cause of the amyotrophic lateral sclerosis/parkinsonism-dementia ... 1954). "Epidemiologic investigations of amyotrophic lateral sclerosis". Neurology. 4 (5): 355-78. doi:10.1212/wnl.4.5.355. PMID ... 2013). "Linking β-methylamino-L-alanine exposure to sporadic amyotrophic lateral sclerosis in Annapolis, MD". Toxicon. 70: 179- ... amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Lewy body disease. In vitro research has shown ...
Antioxidant
... and amyotrophic lateral sclerosis,[18][19] these studies have been inconclusive.[20][21][22] ... and amyotrophic lateral sclerosis". Current Drug Targets. CNS and Neurological Disorders. 2 (2): 95-107. doi:10.2174/ ...
List of neurological conditions and disorders
Lou Gehrig's disease - see Amyotrophic lateral sclerosis. *Lumbar disc disease. *Lumbar spinal stenosis ...
失智症 - 维基百科,自由的百科全书
ALS(英语:Template:Amyotrophic lateral sclerosis). *症狀 *頭頸部 ... 原发性脊髓侧索硬化(英语:Primary lateral sclerosis) ... 弥漫性脱髓鞘硬化(英语:Diffuse myelinoclastic sclerosis) ... 延髓
Lista de revistas científicas de medicina - Wikipédia, a enciclopédia livre
Amyotrophic Lateral Sclerosis (página oficial). *Anaesthesia. *Anesthesia and Analgesia (página oficial). *Anesthesiology ( ...
Polyunsaturated fat
October 2007). "Nutritional status and risk of amyotrophic lateral sclerosis in Japan". Amyotrophic Lateral Sclerosis. 8 (5): ... "Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis". Journal of ... of polyunsaturated fatty acids is under preliminary research to assess the risk of developing amyotrophic lateral sclerosis ( ...
Benedict Cumberbatch
He also set up a recovery fund for the benefit of Amyotrophic Lateral Sclerosis Association.[159][160][161] Cumberbatch has ...
Shark cartilage
... and shark cartilage contains potentially toxic compounds linked to Alzheimer's disease and amyotrophic lateral sclerosis. ...
NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and...
Introduction: Amyotrophic lateral sclerosis (ALS) and Parkinsons disease (PD) are two severe neurodegenerative disorders for ... Amyotrophic lateral sclerosis (ALS), Parkinsons disease (PD), NMR metabolomics, Biomarker, rebrospinal fluid (CSF), Plasma ... NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinsons disease and ...
Amyotrophic lateral sclerosis - Wikipedia
Revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron ... "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 18 (sup 1): 5-10. doi ... Amyotrophic Lateral Sclerosis. CRC Press. p. 9. ISBN 978-0824729240. .. *^ Gordon PH (October 2013). "Amyotrophic Lateral ... Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic ...
CDC - Amyotrophic Lateral Sclerosis: FAQ
Can persons diagnosed with Primary Lateral Sclerosis (PLS) join the National ALS Registry?. Only people diagnosed with ALS can ... Most persons who are first diagnosed with progressive muscular atrophy, progressive bulbar palsy, or primary lateral sclerosis ... Other MNDs include progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis. ...
Amyotrophic Lateral Sclerosis | Encyclopedia.com
Amyotrophic lateral sclerosis Definition Amyotrophic lateral sclerosis (ALS) is a disease that breaks down tissues in the ... AMYOTROPHIC LATERAL SCLEROSIS. DEFINITION. Amyotrophic lateral sclerosis (ALS; pronounced ay-MY-eh-TRO-fik LA-ter-el skler-OH- ... Amyotrophic lateral sclerosis. Definition. Amyotrophic lateral sclerosis (ALS) is a disease that breaks down tissues in the ... Amyotrophic Lateral Sclerosis. Definition. Amyotrophic lateral sclerosis (ALS) is a disease that breaks down tissues in the ...
Amyotrophic lateral sclerosis: MedlinePlus Genetics
Amyotrophic lateral sclerosis (ALS) is a progressive disease that affects motor neurons, which are specialized nerve cells that ... Genetic Testing Registry: Amyotrophic lateral sclerosis type 1 *Genetic Testing Registry: Amyotrophic lateral sclerosis type 10 ... Genetic Testing Registry: Amyotrophic lateral sclerosis type 12 *Genetic Testing Registry: Amyotrophic lateral sclerosis type 2 ... Genetic Testing Registry: Amyotrophic lateral sclerosis *Genetic Testing Registry: Amyotrophic lateral sclerosis 14, with or ...
Global Amyotrophic Lateral Sclerosis Market 2014-2018
The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, ... The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period ... The report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market ... The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market ...
CDC - Amyotrophic Lateral Sclerosis: Research Application Info
Following submission, ATSDR will review the application for completeness and relevance to Registry participants. It will then be evaluated by an external expert panel. ATSDR will not consider any research that does not have IRB approval and an FDA IND or IDE number for an investigational test article, if applicable.. The Registry Web portal provides a tool for researchers to track the status of their applications. ATSDR estimates the approval process could take up to 60 business days from the receipt of a complete application.. If your application for data and/or samples is approved, there will be some additional requirements, e.g., signing a Material Transfer Agreement (MTA) you must complete before you can receive the approved data and/or specimens. You will also be required to submit an annual updates about your project. Annual Update Form.. For questions about how you can work with the Registry, please contact us at 1-877-442-9719 or by email at ...
ALS (Amyotrophic Lateral Sclerosis) | Brain Institute | OHSU
ALS: Amyotrophic Lateral Sclerosis (ALS), The Muscular Dystrophy Association. *Amyotrophic Lateral Sclerosis (ALS) Fact Sheet, ... ALS (Amyotrophic Lateral Sclerosis) Your team of specialists at the ALS and Neuromuscular Disease Center will give you expert ... ALS (amyotrophic lateral sclerosis) is also known as Lou Gehrigs disease after the New York Yankees player who was diagnosed ...
The Treatment of Amyotrophic Lateral Sclerosis | SpringerLink
Many physicians make no effort at treatment for patients suffering from amyotrophic lateral sclerosis (ALS). This is hard to ... Amyotrophic Lateral Sclerosis Methyl Phenidate Amyotrophic Lateral Sclerosis Patient Motor Neuron Disease Calcium Gluconate ... The Treatment of Amyotrophic Lateral Sclerosis. In: Cosi V., Kato A.C., Parlette W., Pinelli P., Poloni M. (eds) Amyotrophic ... F. H. Norris, K. S. U, E. H. Denys, K. C. Archibald, and C. Lebo, Amyotrophic lateral sclerosis (letter), Mayo Clin.Proc., 53: ...
RhymeZone: amyotrophic lateral sclerosis definitions
Amyotrophic Lateral Sclerosis | ALS | Lou Gehrig's disease | MedlinePlus
ALS stands for Amyotrophic Lateral Sclerosis, also called Lou Gehrigs disease. ALS affects the nervous system, causing muscle ... ALS (Amyotrophic Lateral Sclerosis) (National Institute of Neurological Disorders and Stroke) * Amyotrophic Lateral Sclerosis ( ... Amyotrophic lateral sclerosis (Medical Encyclopedia) Also in Spanish * Swallowing problems (Medical Encyclopedia) Also in ... Amyotrophic Lateral Sclerosis (ALS) (National Institute of Neurological Disorders and Stroke) - Short Summary Also in Spanish ...
Redox Regulation in Amyotrophic Lateral Sclerosis
Redox Regulation in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results from the death of upper and lower motor neurons ... "A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease," Amyotrophic Lateral ... "Protein disulfide isomerase-immunopositive inclusions in patients with amyotrophic lateral sclerosis," Amyotrophic Lateral ... Redox Regulation in Amyotrophic Lateral Sclerosis. Sonam Parakh. ,1 Damian M. Spencer. ,1 Mark A. Halloran. ,2 Kai Y. Soo. ,1 ...
Amyotrophic Lateral Sclerosis ALS
Current nano/biotechnological approaches in amyotrophic lateral sclerosis | SpringerLink
Amyotrophic lateral sclerosis (ALS) is a common late-onset neurodegenerative disorder that affects motor neurons. There is no ... Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993; 261:1047-1051.CrossRefGoogle ... A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994; 330(9):585-591.CrossRefGoogle Scholar ... Amyotrophic lateral sclerosis Cu Zn-superoxide dismutase Diagno-therapeutics Nanobiotechnology This is a preview of ...
What is amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease)?
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations ... ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis ... Amyotrophic lateral sclerosis. CD68 immunostaining shows abundant histiocytes in lateral column (ie, corticospinal tract) of ... Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009 Feb 3. 4:3. [Medline]. [Full Text]. ...
Discovery aids understanding of amyotrophic lateral sclerosis
Researchers have discovered a basic molecular mechanism that sheds light on the disease process underlying amyotrophic lateral ... has discovered a basic molecular mechanism that sheds light on the disease process underlying amyotrophic lateral sclerosis ( ... Tags: AIDS, Brain, Cell, Eye, Light, Metabolism, Nucleus, Paralysis, Pathology, Protein, Research, RNA, Sclerosis, Splicing, ... Multiple sclerosis therapies delay progression of disability. *Hearing challenges still reported by high proportion of older ...
Amyotrophic lateral sclerosis | Define Amyotrophic lateral sclerosis at Dictionary.com
Amyotrophic lateral sclerosis definition, an incurable disease of unknown cause in which progressive degeneration of motor ... amyotrophic lateral sclerosis. in Science. amyotrophic lateral sclerosis. [ā′mī-ə-trō′fĭk, -ə-trŏf′ĭk, ā-mī′-] ... amyotrophic lateral sclerosis. amyotrophic lateral sclerosis. noun. *a form of motor neurone disease in which degeneration of ... amyotrophic lateral sclerosis. in Medicine. amyotrophic lateral sclerosis. [ā-mī′ə-trŏf′ĭk, -trō′fĭk] ...
Horae Gene Therapy Strategies for Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Charcot disease after the physician who first described it, and Lou Gehrigs ... Gene Therapy Strategies for Amyotrophic Lateral Sclerosis. What is Amyotrophic Lateral Sclerosis (ALS)?. Amyotrophic lateral ... Muellers gene therapy strategy on Amyotrophic Lateral Sclerosis (ALS). SOD1-linked ALS program. This is our more advanced ... A leading researcher for Amyotrophic Lateral Sclerosis (ALS). Chris Mueller, PhD, is an Associate Professor of Pediatrics and a ...
Amyotrophic Lateral Sclerosis (ALS) Clinical Research Trials | CenterWatch
Amyotrophic Lateral Sclerosis (ALS) Clinical Research Trial Listings in Musculoskeletal Neurology Pulmonary/Respiratory ... Amyotrophic Lateral Sclerosis (ALS) Clinical Trials. A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials ... Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Background Non-invasive mechanical ventilation (NIV) has been ...
Amyotrophic Lateral Sclerosis (ALS) Clinical Research Trials | CenterWatch
Amyotrophic Lateral Sclerosis (ALS) Clinical Research Trial Listings in Musculoskeletal Neurology Pulmonary/Respiratory ... Amyotrophic Lateral Sclerosis (ALS) Clinical Trials. A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials ... Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis In this trial, approximately 200 subjects will participate in ... Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis This is a prospective observational multicentric ...
Amyotrophic lateral sclerosis - Wikipedia
Revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron ... "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 18 (sup 1): 5-10. doi ... see Amyotrophic lateral sclerosis research#Past clinical trials. Wijesekera LC, Leigh PN (February 2009). "Amyotrophic lateral ... "Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar ...
Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. - PubMed - NCBI
Continuum of frontal lobe impairment in amyotrophic lateral sclerosis.. Murphy JM1, Henry RG, Langmore S, Kramer JH, Miller BL ... To identify the nature and prevalence of cognitive and behavioral abnormalities in patients with amyotrophic lateral sclerosis ... Amyotrophic Lateral Sclerosis - Genetic Alliance. *Amyotrophic Lateral Sclerosis - MedlinePlus Health Information. ...
A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis | PNAS
A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Lauren Mifflin, Zhirui Hu, Connor Dufort, ... A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Lauren Mifflin, Zhirui Hu, Connor Dufort, ... A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. View ORCID ProfileLauren Mifflin, Zhirui Hu, ... A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis Message Subject (Your Name) has sent you a ...
Rare variants in MYH15 modify amyotrophic lateral sclerosis risk. - PubMed - NCBI
Amyotrophic lateral sclerosis (ALS) - Symptoms and causes - Mayo Clinic
Amyotrophic lateral sclerosis (ALS). Find out more about the symptoms, diagnosis and treatment of ALS, also known as Lou ... Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system (neurological ... Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology. 2015;7:181.. *Crum BA (expert opinion). Mayo Clinic, ... Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom ...
Amyotrophic lateral sclerosis (ALS) - Diagnosis and treatment - Mayo Clinic
Amyotrophic lateral sclerosis (ALS). Find out more about the symptoms, diagnosis and treatment of ALS, also known as Lou ... Some people with amyotrophic lateral sclerosis live much longer than the three to five years usually associated with this ... Amyotrophic lateral sclerosis (ALS) is difficult to diagnose early because it may mimic several other neurological diseases. ... Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology. 2015;7:181.. *Crum BA (expert opinion). Mayo Clinic, ...
Amyotrophic lateral sclerosis research - Wikipedia
Research on amyotrophic lateral sclerosis has focused on animal models of the disease, its mechanisms, ways to diagnose and ... Kim, Changsung; Lee, Hee Chul; Sung, Jung-Joon (2014-09-01). "Amyotrophic Lateral Sclerosis - Cell Based Therapy and Novel ... Mitsumoto H, Brooks BR, Silani V (November 2014). "Clinical trials in amyotrophic lateral sclerosis: why so many negative ... "Public summary of opinion on orphan designation Masitinib mesilate for treatment of amyotrophic lateral sclerosis" (PDF). EMA. ...
NeurologyNeurodegenerative diseaseSymptomsEvaluation of Amyotrophic Lateral SFunction in Amyotrophic Lateral SBiomarkers in Amyotrophic Lateral SUpper motorPathologyDiagnosisMultiple sclerosisGehrig's DiseaseSpinal musculaAbstractDefine AmyotrophicOnsetPatientsDegenerativeNeurological2019ClinicalDiseasesDiseaseProgressive musculaPathogenesisTreatmentNervesGeneticsBulbarRiluzolePrimaryBehaviouralSporadicGeneticTractsImpairmentVentilationSerumTreatments
Neurology3
- 4,5,7 He stated, "The diagnosis as well as the anatomy and physiology of the condition amyotrophic lateral sclerosis is one of the most completely understood conditions in the realm of clinical neurology. (ajmc.com)
- El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. (freemd.com)
- Prize4Life, a non-profit organization dedicated to accelerating the discovery of a cure for Amyotrophic Lateral Sclerosis (ALS) by offering incentives to drive innovation, today announced that Dr. Seward Rutkove, Chief of the Division of Neuromuscular Disease at Beth Israel Deaconess Medical Center and Associate Professor of Neurology at Harvard Medical School, has received the $1 million dollar Prize4Life award for the discovery of a new ALS biomarker. (highlighthealth.com)
Neurodegenerative disease11
- Amyotrophic lateral sclerosis (ALS) is a disease that breaks down tissues in the nervous system (a neurodegenerative disease) of unknown cause that affects the nerves responsible for movement. (encyclopedia.com)
- Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results from the death of upper and lower motor neurons. (hindawi.com)
- Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. (pnas.org)
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with substantial heterogeneity in its clinical presentation. (nature.com)
- Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting from the loss of upper motor neurons (UMN) and lower motor neurons (LMN). (cap.org)
- Amyotrophic Lateral Sclerosis (ALS) , is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. (psp.org)
- Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. (disabled-world.com)
- Amyotrophic lateral sclerosis (ALS) is a fatal and progressive neurodegenerative disease, which affects motor neurons in the anterior horn of the spinal cord, the brainstem, and the motor cortex. (frontiersin.org)
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the motor nervous system. (broadinstitute.org)
- SOD1 was considered a regional candidate gene because mutations in human SOD1 can cause amyotrophic lateral sclerosis (ALS), an adult-onset fatal paralytic neurodegenerative disease with both upper and lower motor neuron involvement. (pnas.org)
- This paper shows a relationship between mitochondrial haplogroups and, amyotrophic lateral sclerosis, a neurodegenerative disease. (blogspot.com)
Symptoms2
- [19] In 1869, the connection between the symptoms and the underlying neurological problems was first described by Jean-Martin Charcot , who in 1874 began using the term amyotrophic lateral sclerosis . (wikipedia.org)
- Treatments can't reverse the damage of amyotrophic lateral sclerosis, but they can slow the progression of symptoms, prevent complications and make you more comfortable and independent. (mayoclinic.org)
Evaluation of Amyotrophic Lateral S1
- The evaluation of amyotrophic lateral sclerosis begins with a history and physical exam. (freemd.com)
Function in Amyotrophic Lateral S1
- Dietary intake and function in amyotrophic lateral sclerosis: Are they associated? (eurekalert.org)
Biomarkers in Amyotrophic Lateral S1
- Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? (bmj.com)
Upper motor1
- Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. (medscape.com)
Pathology2
- Increased levels of NOS have been observed in the motor neurons of amyotrophic lateral sclerosis (ALS) patients suggesting a role of RNS in pathology [ 7 ]. (hindawi.com)
- Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. (cap.org)
Diagnosis4
- Duke's ALS Center is one of approximately 100 centers in the world dedicated to the diagnosis and treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. (dukehealth.org)
- Is what you eat associated with better function and respiratory function for patients with amyotrophic lateral sclerosis (ALS) soon after diagnosis? (eurekalert.org)
- The diagnosis of amyotrophic lateral sclerosis requires testing. (freemd.com)
- The Section of Amyotrophic Lateral Sclerosis and Related Motor Neuron Disorders in the Neuromuscular Center, headed by Dr. Erik P Pioro since 2000, provides diagnosis and management, as well as various research studies for hundreds of patients annually with ALS and other motor neuron diseases (MNDs) from Ohio and elsewhere. (clevelandclinic.org)
Multiple sclerosis2
- A magnetic resonance imaging (MRI) scan of the head or spine may be used to exclude other conditions that can damage or compress nerve cells such as cervical spondylosis, multiple sclerosis, and thyroid diorders. (medbroadcast.com)
- Glatiramer acetate is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS). (fiercebiotech.com)
Gehrig's Disease22
- Amyotrophic lateral sclerosis ( ALS ), also known as motor neurone disease ( MND ) or Lou Gehrig's disease , is a specific disease that causes the death of neurons controlling voluntary muscles . (wikipedia.org)
- ALS (amyotrophic lateral sclerosis) is also known as Lou Gehrig's disease after the New York Yankees player who was diagnosed with it in 1939. (ohsu.edu)
- Product description The present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's disease provides a competitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig's disease as of March 2009. (slideshare.net)
- Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by the gradual degeneration and death of motor neurons. (slideshare.net)
- Amyotrophic lateral sclerosis, or ALS, is sometimes called Lou Gehrig's disease. (medicinenet.com)
- An international team of researchers has discovered a basic molecular mechanism that sheds light on the disease process underlying amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. (news-medical.net)
- Amyotrophic lateral sclerosis (ALS), also known as Charcot disease after the physician who first described it, and Lou Gehrig's disease in the US after a famous baseball player who suffered from ALS, is a neurodegenerative disorder that primarily affects the motor neurons. (umassmed.edu)
- Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. (centerwatch.com)
- amyotrophic lateral sclerosis (ALS) (ā´mīətrōf´ik, sklĬrō´sĬs) or motor neuron disease, sometimes called Lou Gehrig's disease, degenerative disease that affects motor neurons in the brain and spinal cord , preventing them from sending impulses to the muscles. (questia.com)
- Learning you have amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, can be overwhelming. (dukehealth.org)
- Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease, is a progressive neurological disease that causes the neurons that control voluntary muscles (motor neurons) to degenerate, according to the National Institutes of Health (NIH). (livescience.com)
- A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and related degenerative diseases. (redorbit.com)
- This past May my close friend Brad was diagnosed with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig's disease. (crowdrise.com)
- Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a progressive nervous disorder affecting motor nerves that control the function of voluntary muscles . (medindia.net)
- Amyotrophic lateral sclerosis (ALS) , commonly known as Lou Gehrig's disease, is a progressive neuromuscular disease. (clevelandclinic.org)
- Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a progressive condition caused by the deterioration of the motor neurons in the spinal cord and brain, resulting in paralysis. (ajmc.com)
- Montréal, November 16, 2017 - Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. (eurekalert.org)
- ALS , formally known as amyotrophic lateral sclerosis and informally as Lou Gehrig's disease, occurs in both a less common familial form (i.e. an inherited form, known as ALS1), and perhaps independently, in a sporadic form. (snpedia.com)
- In order to better understand the causes of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a group of scientists at the Centre hospitalier de l'Université de Montréal Research Centre (CRCHUM) studied 29 genes involved in the development of motor neurons in 190 ALS patients from Quebec and France. (healthcanal.com)
- NEW YORK , Sept. 30, 2020 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced today the awarding of five new MDA grants totaling over $1.6 million toward research focused on amyotrophic lateral sclerosis (ALS), commonly known as ' Lou Gehrig's disease. (prnewswire.com)
- Amyotrophic lateral sclerosis (ALS) - commonly known as Lou Gehrig's disease - is a motor neuron disease. (medbroadcast.com)
- Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive wasting away of the nerve cells in the brain and spinal column that control the muscles that allow movement. (conehealth.com)
Spinal muscula2
- Examine biological similarities between ALS and motor neuron disease in other neurodegenerative disorders, including frontotemporal dementia, chronic traumatic encephalopathy, Kennedy's disease, spinal muscular atrophy, and primary lateral sclerosis. (nih.gov)
- Other disorders which fall under the category of motor neuron disease include primary lateral sclerosis, spinal muscular atrophy, and progressive bulbar palsy. (yale.edu)
Abstract1
- Abstract Our objectives were to assess the frequency of behavioural changes in patients with amyotrophic lateral sclerosis (ALS) and to compare the clinical profile of ALS patients with those with behavioural variant frontotemporal dementia (bvFTD). (biomedsearch.com)
Define Amyotrophic1
- How would you define amyotrophic lateral sclerosis? (yourdictionary.com)
Onset7
- Amyotrophic Lateral Sclerosis - Anyone know how fast bulbar onset ALS takes? (drugs.com)
- This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. (centerwatch.com)
- 13 Patients with an older age at symptom onset, bulbar-onset ALS, lower Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS or ALSFRS-R) score, and early dysfunction of the respiratory muscles have a lower survival risk. (ajmc.com)
- Amyotrophic Lateral Sclerosis (ALS), the most common MND, is a fatal adult-onset neuromuscular disease. (clinicaltrials.gov)
- Researchers in Rensselaer Polytechnic Institute's Social and Behavioral Research Lab (SBRL) are leading a study to investigate potential environmental, lifestyle, and medical variables that may contribute to the onset of Amyotrophic Lateral Sclerosis (ALS). (news-medical.net)
- An amyotrophic lateral sclerosis with juvenile onset that has_material_basis_in mutation in the SETX gene on chromosome 9. (jax.org)
- Amyotrophic lateral sclerosis ( ALS ) is the most common type of adult-onset motor neuron disease (MND). (medscape.com)
Patients18
- Many physicians make no effort at treatment for patients suffering from amyotrophic lateral sclerosis (ALS). (springer.com)
- K. S. U, F. H. Norris, E. H. Denys, and C. P. Lebo, Surgery in patients with amyotrophic lateral sclerosis. (springer.com)
- Isis Pharmaceuticals, Inc. ISIS announced that its partner Biogen Inc. BIIB has started a phase I/II study on ISIS-SOD1Rx (previously known as ISIS-BIIB3Rx) in patients suffering from amyotrophic lateral sclerosis (ALS). (nasdaq.com)
- In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients) and is an independent prognostic factor. (centerwatch.com)
- To identify the nature and prevalence of cognitive and behavioral abnormalities in patients with amyotrophic lateral sclerosis (ALS). (nih.gov)
- Data from patients with amyotrophic lateral sclerosis, who reported starting treatments within the last 5 years. (patientslikeme.com)
- The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS). (clinicaltrials.gov)
- Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. (clinicaltrials.gov)
- The approval of edaravone for the treatment of amyotrophic lateral sclerosis by the FDA brings hope to several patients. (medindia.net)
- A tertiary referral centre clinical database was analysed, consisting of 1471 patients with amyotrophic lateral sclerosis seen between 1993 and 2007. (nih.gov)
- The Amyotrophic Lateral Sclerosis (ALS) Multidisciplinary Clinic at Massachusetts General Hospital provides high-quality care along with access to the latest treatments and research opportunities for patients with ALS. (massgeneral.org)
- Resequencing of 29 Candidate Genes in Patients With Familial and Sporadic Amyotrophic Lateral Sclerosis. (healthcanal.com)
- The primary objectives of this study are to determine the safety and efficacy of Amivita, a compound of amino acids and vitamines in patients with Amyotrophic lateral sclerosis (ALS)ALS. (clinicaltrials.gov)
- This study aimed to evaluate muscle oxidative function during exercise in amyotrophic lateral sclerosis patients (pALS) with non-invasive methods in order to assess if determinants of reduced exercise tolerance might match ALS clinical heterogeneity. (nature.com)
- Pattern of lung function decline in patients with amyotrophic lateral sclerosis: implications for timing of noninvasive ventilation. (clevelandclinic.org)
- The study was designed to assess the safety, tolerability and efficacy of glatiramer acetate (GA) 40 mg, given once daily as a subcutaneous injection, in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis (ALS) patients. (fiercebiotech.com)
- Materials and Methods We carried out a retrospective multivariate analysis of 713 patients with ALS over a 20 year period from the South-East England Amyotrophic Lateral Sclerosis (SEALS) population register. (bmj.com)
- By isolating cells from patients' spinal tissue within a few days after death, researchers funded by the National Institutes of Health have developed a new model of the paralyzing disease amyotrophic lateral sclerosis (ALS) . (highlighthealth.com)
Degenerative5
- A severe physical disability has a dramatic impact on a person's life, whether it is caused by a neuro-degenerative disease such as amyotrophic lateral sclerosis (ALS), a brainstem stroke, or a spinal cord injury. (centerwatch.com)
- ALS (amyotrophic lateral sclerosis) is a degenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. (patientslikeme.com)
- Find out more about the degenerative disease- Amyotrophic lateral sclerosis. (medindia.net)
- Amyotrophic lateral sclerosis is a rare degenerative disorder that results in progressive wasting and paralysis of voluntary muscles. (cnbc.com)
- Amyotrophic lateral sclerosis (ALS) is the most frequently occurring of the neuromuscular degenerative disorders, with a median survival time of 3-5 years. (nih.gov)
Neurological8
- Amyotrophic lateral sclerosis is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles. (medicinenet.com)
- Amyotrophic lateral sclerosis (ALS) is a rare group of neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. (medicinenet.com)
- Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by progressive muscular atrophy and respiratory failure. (nih.gov)
- Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system (neurological) disease that destroys nerve cells and causes disability. (mayoclinic.org)
- Amyotrophic lateral sclerosis (ALS) is difficult to diagnose early because it may mimic several other neurological diseases. (mayoclinic.org)
- A Meta-Analysis of Observational Studies of the Association Between Chronic Occupational Exposure to Lead and Amyotrophic Lateral Sclerosis " stems from the Canadian government's $15 million effort to better understand neurological health conditions. (scienceblogs.com)
- Amyotrophic lateral sclerosis (ALS) is a neurological disorder which can reduce the life span of the affected individual. (medindia.net)
- Amyotrophic lateral sclerosis (ALS) is a terminal neurological disorder characterized by progressive degeneration of nerve cells in the spinal cord and brain. (massgeneral.org)
20191
- THURSDAY, Feb. 28, 2019 - Professional soccer players may be vulnerable to amyotrophic lateral sclerosis (ALS), a new study suggests. (drugs.com)
Clinical5
- The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of amyotrophic lateral sclerosis (ALS). (fda.gov)
- Staging criteria for amyotrophic lateral sclerosis would help to provide a universal and objective measure of disease progression with benefits for patient care, resource allocation, research classifications and clinical trial design. (nih.gov)
- The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis. (cnbc.com)
- Waragai M: MRI and clinical features in amyotrophic lateral sclerosis. (freemd.com)
- Objectives To generate a prognostic classification method for Amyotrophic Lateral Sclerosis (ALS) from a prognostic model built using clinical variables from a population register. (bmj.com)
Diseases2
- [2] Motor neuron diseases include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy , pseudobulbar palsy , and monomelic amyotrophy (MMA). (wikipedia.org)
- Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative diseases that are related genetically and pathologically. (mendeley.com)
Disease13
- Introduction: Amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) are two severe neurodegenerative disorders for which the disease mechanisms are poorly understood and reliable biomarkers are absent. (diva-portal.org)
- Amyotrophic lateral sclerosis (ALS) is a progressive disease that affects motor neurons, which are specialized nerve cells that control muscle movement. (medlineplus.gov)
- What is amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease)? (medscape.com)
- A disease of the motor tracts of the lateral columns and anterior horns of the spinal cord, causing progressive muscular atrophy, increased reflexes, fibrillary twitching, and spastic irritability of muscles. (dictionary.com)
- Research on amyotrophic lateral sclerosis has focused on animal models of the disease, its mechanisms, ways to diagnose and track it, and treatments. (wikipedia.org)
- Amyotrophic lateral sclerosis (ALS) is a disease in which the motor neurons die in a progressive manner, leading to paralysis and muscle wasting. (diva-portal.org)
- Amyotrophic lateral sclerosis (ALS) is a disease that results in the progressive deterioration and loss of function of the motor neurons in the brain and spinal cord, leading to paralysis. (ajmc.com)
- 6 In 1874, Charcot named this disease, "amyotrophic lateral sclerosis," which is still known today as Charcot disease in many parts of the world. (ajmc.com)
- Amyotrophic lateral sclerosis, or ALS, is a disease in which certain nerve cells in the brain and spinal cord slowly die. (adventisthealthcare.com)
- Brandeis researchers have made a significant advance in the effort to understand amyotrophic lateral sclerosis (ALS) by successfully reversing the toxicity of the mutated protein in the familial type of the disease. (innovations-report.com)
- A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide. (mcgill.ca)
- Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain, brain stem and spinal cord that control voluntary muscle movement. (mountsinai.org)
- This higher incidence does not appear to be due to familial ALS or en environmental factor, such as an infective agent, but is thought to be due to higher susceptibility to the disease by the islands native population. (yale.edu)
Progressive muscula3
- [17] Primary lateral sclerosis (PLS) involves only upper motor neurons, and progressive muscular atrophy (PMA) involves only lower motor neurons. (wikipedia.org)
- Other MNDs include progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis. (cdc.gov)
- Primary lateral sclerosis (PLS) involves only upper motor neurons, and progressive muscular atrophy (PMA) involves only lower motor neurons. (wikipedia.org)
Pathogenesis2
- Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. (cap.org)
- Mitochondrial impairment has been implicated in the pathogenesis of the amyotrophic lateral sclerosis (ALS). (blogspot.com)
Treatment4
- The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins, peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). (slideshare.net)
- NEW YORK (GenomeWeb) - Researchers have uncovered a protein that may serve as a marker for amyotrophic lateral sclerosis and could be used to ascertain whether certain treatment approaches are working. (genomeweb.com)
- PARIS, March 20, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis. (cnbc.com)
- The successful application submitted by AB Science and the FDA granting of Orphan Drug status entitles the company to a seven-year period of marketing exclusivity in the United States for masitinib, if it is approved by the FDA for the treatment of amyotrophic lateral sclerosis. (cnbc.com)
Nerves2
- Lateral" indicates one of the regions of the spinal cord affected, and "sclerosis" describes the hardened tissue that develops in place of healthy nerves. (encyclopedia.com)
- 3 "Lateral" denotes the areas where the nerves that signal muscles are located in the spinal cord. (ajmc.com)
Genetics2
- The genetics and neuropathology of amyotrophic lateral sclerosis. (cap.org)
- Here is some additional information about the 'genetics' of this condition that was written by our Genetic Counselor and other genetic professionals: http://www.accessdna.com/condition/Amyotrophic_Lateral_Sclerosis/35. (blogspot.com)
Bulbar1
- Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. (clevelandclinic.org)
Riluzole1
- Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. (clevelandclinic.org)
Primary2
- Primary lateral sclerosis. (medscape.com)
- Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. (clevelandclinic.org)
Behavioural1
- How common are behavioural changes in amyotrophic lateral sclerosis? (biomedsearch.com)
Sporadic1
- Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis? (blogspot.com)
Genetic1
- Our knowledge of the genetic contribution to Amyotrophic Lateral Sclerosis (ALS) is rapidly growing, and there is increasing research into how ALS spreads through the motor system and beyond. (bl.uk)
Tracts1
- Secondary degeneration of white matter tracts is common and prominent in the lateral and ventral funiculi of the spinal cord containing the lateral and anterior corticospinal tracts, respectively. (cap.org)
Impairment2
Ventilation1
- Variation in noninvasive ventilation use in amyotrophic lateral sclerosis. (clevelandclinic.org)
Serum1
- The aim of this study is to determine whether serum uric acid levels predict survival in amyotrophic lateral sclerosis (ALS). (biomedsearch.com)
Treatments1
- FDA recognizes the critical unmet medical need for new, effective treatments for amyotrophic lateral sclerosis (ALS). (fda.gov)